Second-line Treatment

Also known as: Second-line Therapy / Second Line Treatment / Second line treatment (procedure)

Drug	Drug Name	Drug Description
DB00112	Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
DB00337	Pimecrolimus	A topical calcineurin inhibitor used in the treatment of mild-moderate atopic dermatitis who are not candidates for other types of therapy due to previous lack of response or other reasons.

Drug	Drug Name	Target	Type
DB00112	Bevacizumab	Vascular endothelial growth factor A	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit A	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit B	target
DB00112	Bevacizumab	Complement C1q subcomponent subunit C	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
DB00112	Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
DB00112	Bevacizumab	High affinity immunoglobulin gamma Fc receptor I	target
DB00337	Pimecrolimus	Peptidyl-prolyl cis-trans isomerase FKBP1A	target
DB00337	Pimecrolimus	Serine/threonine-protein kinase mTOR	target
DB00337	Pimecrolimus	Cytochrome P450 3A4	enzyme

Drug	Drug Name	Phase	Status	Count
DB15043	Toripalimab	1	Unknown Status	1
DB08875	Cabozantinib	2	Active Not Recruiting	1
DB16680	Cadonilimab	2	Recruiting	1
DB05928	Dovitinib	2	Completed	1
DB14765	Rivoceranib	2	Completed	1